Article preview from “The Pink Sheet”-   March 28, 2011 Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows. A […]

“One area of criminal enforcement that will be a focus for the Criminal Division in the months and years ahead [is the] application of the Foreign Corrupt Practices Act (FCPA) to the pharmaceutical industry. We will be vigilant in holding companies and individuals who break the law accountable, not only through civil actions … but

“Pharma and Device Companies are the Next Target for FCPA Investigations”Read More »